Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events). Stock consideration issued privately under Securities Act Section 4(a)(2) and/or Regulation D exemptions.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Stock consideration issued privately under Securities Act Section 4(a)(2) and/or Regulation D exemptions
- Only accredited Alkeus investors eligible to receive upfront or contingent Tarsus shares
- Private issuance avoids public offering registration but limits participation to qualified investors
Item 8.01 · Other Events
- August 6, 2026 press release announces a Merger Agreement, with transaction details in Exhibit 99.1
- Acquisition outcome remains subject to closing, creating execution and transaction-completion risk
- Potential investor impacts include strategic benefits, milestone payments, royalty payments, and resale registration timing
- Forward-looking statements remain subject to SEC-filed risk factors and may differ materially from expectations
Other items in this filing:
- Item 3.02: Unregistered Sales of Equity Securities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.